Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Arsenal Biosciences, Inc. is currently managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These filings are being reviewed by 2 distinct examiners, which indicates that the company's current prosecution efforts are not concentrated under a single individual. The workload is also divided between 2 distinct art units, suggesting that the underlying technologies fall into different specialized categories within the biotechnology sector.
The busiest examiner identified for the portfolio is YU, DELPHINUS DOU YI, who is handling 1 busiest examiner pending action. This accounts for 1 of the 2 pending office actions currently active for the company. With 2 distinct examiners and 2 distinct art units involved, the company must prepare for varied feedback and examination criteria. The strategy for resolving these 2 pending office actions will likely involve distinct technical arguments tailored to the specific requirements of each art unit. Practitioners should monitor the progress with YU, DELPHINUS DOU YI as a key component of the overall prosecution landscape.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, DELPHINUS DOU YI | 1 | 33.3% | +0.0% |
| YU, DAVID TUYANG | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18308481 | COMPOSITIONS AND METHODS OF GENOMIC MODIFICATION OF CELLS AND USES THEREOF | YU, DAVID TUYANG | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18379912 | NON-VIRAL HOMOLOGY MEDIATED END JOINING | YU, DELPHINUS DOU YI | 1636 | §103 | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18308481 | COMPOSITIONS AND METHODS OF GENOMIC MODIFICATION OF CELLS AND USES THEREOF | YU, DAVID TUYANG | 1635 | §102§103§112 | Non-Final OA | — | Pending | Apr 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialArsenal Biosciences, Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Delphinus Dou Yi Yu has the most, with 1 of Arsenal Biosciences, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
